KBC Group
TARS icon

KBC Group’s Tarsus Pharmaceuticals TARS Stock Holding History

KBC Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$102K Hold
1,296
– – ﹤0.01% 1374
2026
Q2 		$82K Hold
1,296
– – ﹤0.01% 1519
2026
Q1 		$91K Hold
1,296
– – ﹤0.01% 1379
2025
Q4 		$106K Hold
1,296
– – ﹤0.01% 1235
2025
Q3 		$77K Buy
+1,296
New +$63.8K ﹤0.01% 1431

Other funds holding TARS

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

KBC Group's TARS Position: Q3 2026 in Review

KBC Group held its Tarsus Pharmaceuticals (TARS) position steady in Q3 2026 at 1,296 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

KBC Group first reported a position in TARS in Q3 2025 and has held it in 5 quarters since. The position peaked at $106K in Q4 2025. 176 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

  • KBC Group held 1,296 shares of Tarsus Pharmaceuticals worth $102K as of Q3 2026.
  • KBC Group left its Tarsus Pharmaceuticals share count unchanged in Q3 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1374 holding.
  • KBC Group first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • KBC Group's Tarsus Pharmaceuticals position peaked at $106K in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.